Granules India signs outsourcing deal with Matchland Pty Ltd of Australia
Granules India Ltd; a leading pharmaceutical formulation intermediates company with complete vertical integration, today announced that it has entered into an outsourcing agreement with Matchland Pty Ltd, (trading as New Products Development). Under the agreement, New Products Development will outsource its finished dosage manufacturing requirement to Granules India for the Australian market.
Five products have been identified for the initial manufacturing and this list is expected to grow as the relationship progresses. The agreement is in the nature of a partnership wherein, New Products Development will compensate Granules for all the costs incurred in manufacturing and will also provide a transparent profit margin. This would be New Products Development’s first Outsourcing Agreement with any Indian Company and it effectively complements Granules strategy of expansion into lesser explored markets like Australia and New Zealand.
Commenting on the deal, Mr. C. Krishna Prasad, Managing Director said, “We are planning to use our TGA approved pilot manufacturing capabilities to kickstart the manufacturing as soon as possible.”
Granules recently approved the allotment of 14.9 per cent stake to US-based Ridgeback Capital Investment LLC. The company will issue 22, 11, 200 equity shares of Rs.10/- each fully paid-up at Rs.105.50 per share (including premium) to Ridgeback Capital or their affiliates on a preferential basis.
Sourced From: Adfactors Public Relations Pvt Ltd
Granules India stock price
On July 27, 2015, Granules India closed at Rs 114.65, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 115.60 and the 52-week low was Rs 52.51.
The company's trailing 12-month (TTM) EPS was at Rs 5.33 per share as per the quarter ended June 2015. The stock's price-to-earnings (P/E) ratio was 21.51. The latest book value of the company is Rs 20.76 per share. At current value, the price-to-book value of the company is 5.52.
READ MORE ON Granules India , pharmaceutical formulation , outsourcing agreement , Matchland Pty Ltd, C. Krishna Prasad, Ridgeback Capital Investment LLC
Set email alert for
ADS BY GOOGLE
video of the day
EMs to be volatile near term; Nifty Dec target at 8600: UBS